0001628280-24-010146.txt : 20240311 0001628280-24-010146.hdr.sgml : 20240311 20240311075134 ACCESSION NUMBER: 0001628280-24-010146 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 EFFECTIVENESS DATE: 20240311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LianBio CENTRAL INDEX KEY: 0001831283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40947 FILM NUMBER: 24736567 BUSINESS ADDRESS: STREET 1: 103 CARNEGIE CENTER DRIVE, SUITE 309 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 486-2308 MAIL ADDRESS: STREET 1: 103 CARNEGIE CENTER DRIVE, SUITE 309 CITY: PRINCETON STATE: NJ ZIP: 08540 25 1 lianbio-form25.htm 25 Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.
Commission File Number001-40947
LianBio
The Nasdaq Global Market
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
103 Carnegie Center Drive, Suite 309
Princeton, NJ 08540 (609) 486-2308
(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)
American Depositary Shares, each representing one ordinary share, par value $0.000017100448 per share
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
☐ 17 CFR 240.12d2-2(a)(1)
☐ 17 CFR 240.12d2-2(a)(2)
☐ 17 CFR 240.12d2-2(a)(3)
☐ 17 CFR 240.12d2-2(a)(4)
☐ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1
☒ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements of the Securities Exchange Act of 1934, LianBio certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
March 11, 2024By: /s/ Adam StoneInterim Chief Executive Officer
DateName: Adam StoneTitle
SEC 1654
(03-06)		Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.